Imcyse is a biomedical company founded in July 2010 by Professor Jean-Marie Saint-Remy and is based on a proprietary technology platform resulting from the work carried out by his research group at the Catholic University of Leuven (KUL), Belgium.

The technology platform is based on the finding that certain peptide vaccines generate cytolytic T cells that specifically suppress the immune response underlying the disease mechanisms The technology of Imcyse is applicable where an HLA class II restricted T cell response is involved.